Clearmind reported no serious adverse events and continued good tolerability in six additional patients completing treatment in the second cohort of its ongoing Phase I/IIa trial of CMND-100 for alcohol use disorder. The signal mirrors the first cohort and follows earlier Data and Safety Monitoring Board clearance to advance. No new efficacy data were disclosed.
The study is a multinational, multicenter evaluation of safety, tolerability, pharmacokinetics, and preliminary efficacy for CMND-100, an oral, MEAI‑based, non‑hallucinogenic candidate positioned for moderate to severe AUD. Treatment in the second cohort was completed across Johns Hopkins University in the U.S. and two Israeli sites, Tel Aviv Sourasky Medical Center and Hadassah Medical Center. With cohort two treatment now finished, the program consolidates a clean safety read across sequential cohorts and maintains timeline momentum at a point when many psychedelic-adjacent programs are slowed by psychotherapy logistics and site capacity constraints.
Strategically, Clearmind is leaning into a non‑hallucinogenic psychoplastogen thesis as a counterweight to psychedelic-assisted models that require therapist-intensive protocols, dedicated dosing suites, and extensive monitoring. If sustained, a benign safety profile paired with an outpatient, oral regimen could translate into simpler site workflows, lower per‑patient costs, and fewer regulatory and operational frictions, including reduced need for REMS‑like controls or specialized staff training. It also sidesteps the blinding challenges inherent in psychedelic trials, a known confounder that inflates placebo-adjusted effect sizes and complicates regulatory interpretation. The trade-off is that CMND‑100 will have to demonstrate clinically meaningful reductions in heavy drinking without the behavioral scaffolding that often accompanies psychedelic interventions.
For sites and CROs, a tolerable, non‑hallucinogenic AUD therapy suggests higher throughput and more standard visit schedules, which is material amid persistent staffing shortages and procedure backlogs. Sponsors and vendors focused on decentralized or hybrid designs could find this mechanism more compatible with remote data capture, including ePROs for craving and drinking behavior, wearable or transdermal alcohol sensing, and biomarkers like PEth to validate self‑report. Regulators will focus on hepatic safety in a population with baseline liver risk, potential drug–drug interactions with commonly co‑prescribed psychiatric agents, and signals of abuse liability, all of which drive monitoring burdens and ultimately label scope. Patients stand to benefit from a treatment paradigm that does not require supervised dosing days or psychotherapy appointments, provided efficacy is competitive with existing pharmacotherapies where placebo response is high and adherence is variable.
The immediate next milestone is a fuller Phase I/IIa readout with PK profiles and any preliminary efficacy signals such as changes in percent heavy drinking days, overall consumption, craving scales, and durability beyond the acute dosing window. Dose-ranging clarity will matter, as will whether the sponsor elects a randomized, placebo‑controlled Phase IIb with modern endpoints favored by FDA and EMA, including reductions in World Health Organization drinking risk levels. The key risks are straightforward: small‑N, open‑label safety wins do not de‑risk efficacy, AUD trials are notoriously susceptible to regression to the mean and high placebo response, and an efficacy bar that fails to clear existing generics will struggle to justify adoption. Watch for the Phase IIb design choices around biomarker integration, remote verification of drinking, and inclusion of common comorbidity strata; those decisions will signal confidence in effect size and operational scalability. If Clearmind can pair its emerging tolerability profile with a robust, durable reduction in heavy drinking, the non‑hallucinogenic pathway could gain real traction in a category searching for scalable, clinic‑friendly options.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
